Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06655818
Status:
TERMINATED
Last Update Posted:
None
First Post:
2024-10-22
Brief Title:
Sub-study of Belantamab Mafodotin GSK2857916 as Monotherapy and in Combination With Dostarlimab GSK4057190 in Participants With RRMM
Sponsor:
Organization:
None